

August 5, 2026

Dear Pharmaceutical Manufacturer:

Arizona's Medicaid Program, the Arizona Health Care Cost Containment System (AHCCCS), has contracted with Prime Therapeutics to secure supplemental rebates for preferred agents on the AHCCCS Drug List. The AHCCCS Drug List is utilized by both the Fee-For-Service and Managed Care Organization (MCO) programs.

The intent of AHCCCS is to accrue rebates on both Fee-For-Service and Managed Care utilization for preferred agents under the AHCCCS drug list which is managed by the AHCCCS for covered outpatient drugs dispensed to persons eligible in Arizona for Medicaid, the Children's Health Insurance Program and to persons with Serious Mental Illness, as defined in A.R.S. 36-550, who qualify for state funded care under A.R.S. 36-3408. The AHCCCS supplemental rebate agreement, drafted with the express purpose of establishing a single drug list and described further in section 2.1 of the ARIZONA HEALTH CARE COST CONTAINMENT SYSTEM SUPPLEMENTAL DRUG-REBATE AGREEMENT (SRA), was approved by CMS on May 28, 2015.

SRA 2.1 It is the intent of this Agreement that the State will receive Supplemental Rebates, in addition to the rebates received under Manufacturer's CMS Agreement, pursuant to Section 1927 of the Social Security Act (42 U.S.C. §1396r-8), for the Manufacturer's Supplemental Covered product(s) quarterly utilization in the Arizona Medicaid Program, including all Fee-For-Service and Managed Care beneficiaries, in which there is Medicaid federal financial participation. The parties also intend for this Agreement to meet the requirements of federal law at Section 1927 of the Social Security Act (42 U.S.C. §1396r-8).

The next P&T Meeting is scheduled for October 7, 2026, and will be held virtually beginning at Noon and ending at 5 PM.

At this time, supplemental rebate offers are not requested for the following products and therapeutic categories which will be reviewed at the Pharmacy and Therapeutics Committee:

- | | |
|--------------------------------------|--------------------------------|
| • Analgesics Narcotics, Short Acting | • Calcium Channel Blockers |
| • Angiotensin Modulators | • Contraceptives |
| • Angiotensin Modulator Combinations | • Hypoglycemics, DPP4s |
| • Anticonvulsants | • Intranasal Rhinitis Agents |
| • Antifungals – Oral | • Lipotropics, Statins |
| • Antifungals – Topical | • Ophthalmics, Glaucoma Agents |
| • Antihistamines, Minimally Sedating | • Phosphate Binders |
| • Antimigraine – Triptans | |

At this time, supplemental rebate offers are requested for the following products and therapeutic categories which will be reviewed at the Pharmacy and Therapeutics Committee:

- HIV / AIDS
- Lipotropics, Other
- Potassium Binders
- Sickle Cell Anemia

Supplemental rebates for products selected for the Preferred Drug List will begin to accrue January 1, 2027 and end December 31, 2027.

New Drug Reviews

1. Yuviwel
2. Wainua
3. Idvynso
4. Bysanti
5. Baxfendy
6. Xocova
7. Lynavoy
8. Tepezza

Sincerely,



Theresa Costales
Chief Medical Officer